Precision medicine is rapidly gaining traction in pediatrics. Although traditionally associated with adult care, internal medicine has become an essential contributor to the advancement of precision approaches for young patients. The growing overlap between internal medicine and pediatrics lies in translational research, technological innovation, and collaborative subspecialty care. Internal medicine has played a key role in developing genomic, proteomic, and bioinformatic tools that now underpin pediatric precision medicine. These advances enable clinicians to identify children at high risk for specific diseases, predict disease trajectories, and select the most effective therapies with minimal side effects. This review examines the evolving landscape of pediatric precision medicine, emphasizing how internal medicine research and interspecialty collaboration drive innovation in pediatric diagnostics and therapeutics. By analyzing current research and clinical practices, we aim to clarify the translational and collaborative role of internal medicine in delivering personalized care to children.
DimitriP.Precision diagnostics in children. Camb Prism Precis Med. 2023;1:e17. doi:10.1017/pcm.2023.4.
2.
Al-DewikNIYounesSNEssaMMPathakSQoronflehMW.Making biomarkers relevant to healthcare innovation and precision medicine. Processes. 2022;10(6):1107. doi:10.3390/pr10061107.
3.
ElzagallaaiABarkerCLewisTCohnRRiederM.Advancing precision medicine in paediatrics: past, present and future. Camb Prism Precis Med. 2023;1:e11. doi:10.1017/pcm.2022.14.
4.
DhoundiyalSSrivastavaSKumarS, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29(1):26. doi:10.1186/s40001-023-01627-0.
5.
LeslieLKOrrCJTurnerAL, et al. Child health and the US pediatric subspecialty workforce: planning for the future. Pediatrics. 2024;153(suppl 2):e2023063678B.
6.
WatersALemaireM. Molecular diagnosis of genetic diseases of the kidney: primer for pediatric nephrologists. In: SchaeferFGreenbaumLA, eds. Pediatric Kidney Disease. Cham: Springer; 2023:119-169.
7.
BassareoPPChessaMDi SalvoGWalshKPMcmahonCJ.Strategies to aid successful transition of adolescents with congenital heart disease: a systematic review. Children. 2023;10(3):423. doi:10.3390/children10030423.
8.
LiuQLiCYangL, et al. Weight status change during four years and left ventricular hypertrophy in Chinese children. Front Pediatr. 2024;12:1371286. doi:10.3389/fped.2024.1371286.
9.
ZhouYLiLYuZ, et al. Dermatophagoides pteronyssinus allergen Der p 22: cloning, expression, IgE-binding in asthmatic children, and immunogenicity. Pediatr Allergy Immunol. 2022;33(8):e13835. doi:10.1111/pai.13835.
10.
HopkinsKDziedzicCQadirA, et al. Guidelines in pediatric cardiology. In: AbdullaR-iBergerSBackerC, et al., eds. Pediatric Cardiology: Fetal, Pediatric, and Adult Congenital Heart Diseases. Cham: Springer; 2024:2919-3010.
11.
KhojaAAndraweeraPHLassiZS, et al. Risk factors for early versus late-onset coronary heart disease (CHD): systematic review and meta-analysis. Heart Lung Circ. 2023;32(11):1277-1311. doi:10.1016/j.hlc.2023.07.010.
12.
Al-ObaidiADAliAMAhmadSSKhalaf AKs HashimATMohammedMQ. Double Inlet Left Ventricle. In: TagarakisGSarfanAGHashimHTVarneyJ, eds. Clinical and Surgical Aspects of Congenital Heart Diseases: Text and Study Guide. Cham: Springer; 2023:155-164.
13.
VoCHBushmanGAKleimanZIQuiñónezZAKleimanZIQuiñónezZA. Tetralogy of Fallot. In: DabbaghAConteAHLubinLN, eds. Congenital Heart Disease in Pediatric and Adult Patients: Anesthetic and Perioperative Management. Cham: Springer; 2023:437-468.
14.
YasuharaJGargV.Genetics of congenital heart disease: a narrative review of recent advances and clinical implications. Transl Pediatr. 2021;10(9):2366-2386. doi:10.21037/tp-21-297.
15.
BragançaJPintoRSilvaBMarquesNLeitãoHSFernandesMT.Charting the path: navigating embryonic development to potentially safeguard against congenital heart defects. J Pers Med. 2023;13(8):1263. doi:10.3390/jpm13081263.
16.
KhouryMJBowenSDotsonWD, et al. Health equity in the implementation of genomics and precision medicine: a public health imperative. Genet Med. 2022;24(8):1630-1639. doi: 10.1016/j.gim.2022.04.009.
17.
NewlandDMLawYMAlbersEL, et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146-152. doi: 10.1007/s00246-022-02983-0.
18.
LaeerSCawelloWBurckhardtBB, et al. Enalapril and enalaprilat pharmacokinetics in children with heart failure due to dilated cardiomyopathy and congestive heart failure after administration of an orodispersible enalapril minitablet (LENA-Studies). Pharmaceutics. 2022;14(6):1163. doi:10.3390/pharmaceutics14061163.
19.
HaddadCNAliSStephanouDAssakuraMSSahagianLTrogkanisE.Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Hellenic J Cardiol. 2023;74:58-64. doi:10.1016/j.hjc.2023.06.007.
20.
TownsendMJeewaAKhouryMCunninghamCGeorgeKConwayJ.Unique aspects of hypertrophic cardiomyopathy in children. Can J Cardiol. 2024;40(5):907-920. doi:10.1016/j.cjca.2024.01.013.
21.
WaltonMWagnerJB.Pediatric beta blocker therapy: a comprehensive review of development and genetic variation to guide precision-based therapy in children, adolescents, and young adults. Genes. 2024;15(3):379. doi:10.3390/genes15030379.
22.
WagnerDKronickSNawerHCranfordJBradleySNeumarR.Comparative effectiveness of amiodarone and lidocaine for the treatment of in-hospital cardiac arrest. Chest. 2023;163(5):1109-1119. doi:10.1016/j.chest.2022.10.024.
23.
BatraASSilkaMJBorquezA, et al. Pharmacological management of cardiac arrhythmias in the fetal and neonatal periods: a scientific statement from the American Heart Association. Circulation. 2024;149(10):e937-e952. doi:10.1161/cir.0000000000001206.
XuYZhangMChenY, et al. Does sacubitril/valsartan work in children with heart failure?—a pilot study. Front Cardiovasc Med. 2023;10:1274990. doi:10.3389/fcvm.2023.1274990.
26.
MoranCSchoenmakersNHalsallD, et al. Approach to the patient with raised thyroid hormones and nonsuppressed TSH. J Clin Endocrinol Metab. 2024;109(4):1094-1108. doi:10.1210/clinem/dgad681.
27.
RoseSRWassnerAJWintergerstKA, et al. Congenital hypothyroidism: screening and management. Pediatrics. 2023;151(1):e2022060419. doi:10.1542/peds.2022-060419.
28.
KleinKOMaurasNNayakS, et al. Efficacy and safety of leuprolide acetate 6-month depot for the treatment of central precocious puberty: a phase 3 study. J Endocr Soc. 2023;7(7):bvad071. doi:10.1210/jendso/bvad071.
29.
BizzarriCCapalboDWasniewskaMGBaronioFGrandoneACappaM.Adrenal crisis in infants and young children with adrenal insufficiency: management and prevention. Front Endocrinol (Lausanne). 2023;14:1133376. doi:10.3389/fendo.2023.1133376.
30.
TlemsaniCLarousserieFDe PercinS, et al. Biology and management of high-grade chondrosarcoma: an update on targets and treatment options. Int J Mol Sci. 2023;24(2):1361. doi:10.3390/ijms24021361.
31.
Nur Sunar YaylaEYıldızÇEsmeray ŞenolPKaraçayırNGezgin YıldırımDBakkaloğluSA. How safe are biological agents in pediatric rheumatology. Turk Arch Pediatr. 2024;59(2):185-192. doi:10.5152/turkarchpediatr.2024.23221.
32.
SchuelkeMRBassiriHBehrensEM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603-5607. doi:10.1182/bloodadvances.2023010712.
33.
RamananAVQuartierPOkamotoN, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555-570. doi:10.1016/S0140-6736(23)00921-2.
34.
ChangCVongCWangX, et al. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT Pharmacometrics Syst Pharmacol. 2024;13(4):599-611. doi:10.1002/psp4.13104.
35.
LinT-WLinY-THuY-CYuH-HChiangB-L.Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus. Lupus Sci. Med. 2024;11(1):e000987. doi:10.1136/lupus-2023-000987.
36.
KontakiEMerchantAGaynorEKiparissiF.P494 Efficacy and safety of Upadacitinib in moderate to severe paediatric Crohn’s disease and ulcerative colitis in a tertiary Paediatric IBD (PIBD) centre: a case series. J Crohns Colitis. 2024;18(suppl_1):i986-i986. doi:10.1093/ecco-jcc/jjad212.0624.
37.
LeeSYangMHKimJS, et al. Evaluation of off-label medication use and drug safety in a pediatric intensive care unit. Saudi Pharm J. 2023;31(9):101704. doi:10.1016/j.jsps.2023.101704.
38.
SavageMODonaldsonMDDaviesJHStorrHL.Key stages in the development and establishment of padiatric endocrinology: a template for feature progress. Horm Res Paediatr. 2024;97:22-27. doi:10.1159/000530841.
OrçunAYildizZKöroğlu DağdelenL.Pediatric reference intervals for free testosterone, 17-OH progesterone, androstenedione, and IGF-1 with chemiluminescence immunoassay. Steroids. 2022;186:109078. doi:10.1016/j.steroids.2022.109078.
41.
O’ConnellMAAtlasGAyersKSinclairA.Establishing a molecular genetic diagnosis in children with differences of sex development: a clinical approach. Horm Res Paediatr. 2023;96(2):128-143. doi:10.1159/000520926.
42.
HanafyAKMujtabaBRoman-ColonAM, et al. Imaging features of adrenal gland masses in the pediatric population. Abdom Radiol (NY). 2020;45(4):964-981. doi:10.1007/s00261-019-02213-x.
43.
Ergun-LongmireBRowlandDDeweyJVining-MaravoloP.A narrative review: an update on primary adrenal insufficiency (PAI) in pediatric population. Pediatr Med. 2023;30:6. doi:10.21037/pm-22-2.
44.
SiposJARingelMD.Molecular testing in thyroid cancer diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101680. doi:10.1016/j.beem.2022.101680.
45.
SahakianNCastinettiFRomanetPReznikYBrueT.Updates on the genetics of multiple endocrine neoplasia. Ann Endocrinol (Paris). 2024;85(2):127-135. doi:10.1016/j.ando.2023.11.005.
46.
GippertSWagnerMBrunetT, et al. Exome sequencing (ES) of a pediatric cohort with chronic endocrine diseases: a single-center study (within the framework of the TRANSLATE-NAMSE project). Endocrine. 2024;85(1):444-453. doi:10.1007/s12020-023-03581-7.
47.
GuptaAAggarwalA.Pediatric rheumatology: the last bastion of pediatrics. Indian J Pediatr. 2024;91(9):919-920. doi:10.1007/s12098-024-05040-1.
48.
ReiffDDBridgesJMRifeEC, et al. Majority of new patient referrals to a large pediatric rheumatology center result in non-rheumatic diagnosis. Pediatr Rheumatol. 2023;21(1):120. doi:10.1186/s12969-023-00910-y.
49.
GibsonK.Assessment of Biological Markers to Aid Subtype Classification in Pediatric Primary Systemic Vasculitis. University of British Columbia; September 6, 2023. Accessed May 13, 2025. https://open.library.ubc.ca/media/stream/pdf/24/1.0435766/3.
50.
GarcíaBPesántezMCarbacaV, et al. Systemic lupus erythematosus: update on the diagnosis, prevalence, clinical management, inflammatory markers, new horizons in the pathogenesis, manifestations, and progress in treatment. EPRA Int J Multidiscip Res. 2024:317-325. doi:10.36713/epra15894.
51.
de SousaRNTascilarKCorteG, et al. Metabolic and molecular imaging in inflammatory arthritis. RMD Open. 2024;10(1):e003880. doi:10.1136/rmdopen-2023-003880.
52.
MoltrasioCRomagnuoloMMarzanoAV.NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: from cryopyrin function to targeted therapies. Front Immunol. 2022;13:1007705. doi:10.3389/fimmu.2022.1007705.
53.
GrayPEDavidC.Inborn errors of immunity and autoimmune disease. J Allergy Clin Immunol Pract. 2023;11(6):1602-1622. doi:10.1016/j.jaip.2023.04.018.
54.
FoeldvariITorokKSAntónJ, et al. Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance-the result of the International Hamburg Consensus Meeting December 2022. Expert Rev Clin Immunol. 2024;20(4):387-404. doi:10.1080/1744666x.2023.2298354.
55.
SharmaSBasuSGoyalRKSahooPKMathurR.Rituximab, a safer option for rheumatoid arthritis: a comparison of the reported adverse events of approved monoclonal antibodies. J Pharmacol Pharmacother. 2022;13(4):330-340. doi:10.1177/0976500X231154743.
56.
HanGTHeavnerHSRainsTRHoangAHStoneAL.Chronic pain in autistic youth: clinical prevalence and reflections on tailoring evidence-based interventions from an Interdisciplinary Treatment Team. Children. 2024;11(3):312. doi:10.3390/children11030312.
57.
LernerDGMencinANovakI, et al. Advances in pediatric diagnostic endoscopy: a state-of-the-art review. JPGN Rep. 2022;3(3):e224. doi:10.1097/pg9.0000000000000224.
58.
SauerCGBarnardJAVinciRJStropleJA.Child health needs and the pediatric gastroenterology workforce: 2020–2040. Pediatrics. 2024;153(suppl 2):e2023063678K. doi:10.1542/peds.2023-063678k.
59.
HarroldECStadlerZK.Upper gastrointestinal cancers and the role of genetic testing. Hematol Oncol Clin North Am. 2024;38(3):677-691. doi:10.1016/j.hoc.2024.01.006.
60.
VottoMNasoMBrambillaI, et al. Eosinophilic gastrointestinal diseases in inborn errors of immunity. J Clin Med. 2023;12(2):514. doi:10.3390/jcm12020514.
KimJHYiDYLeeYM, et al. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine. 2022;101(32):e29968. doi:10.1097/MD.0000000000029968.
63.
MuralinathEPrasadMGSharletS.Clinical Review Articles in Physio Pharmacology. Solapur, India: Laxmi Book Publication; 2024.
64.
TrubickaJGrajkowskaWDembowska-BagińskaB.Molecular markers of pediatric solid tumors—diagnosis, optimizing treatments, and determining susceptibility: current state and future directions. Cells. 2022;11(7):1238. doi:10.3390/cells11071238.
65.
FreedmanJLBeelerDMBowersA, et al. Supportive care in pediatric oncology: opportunities and future directions. Cancers. 2023;15(23):5549. doi:10.3390/cancers15235549.
66.
PankiwMBrezden-MasleyCCharamesGS.Comprehensive genomic profiling for oncological advancements by precision medicine. Med. Oncol. 2023;41(1):1. doi:10.1007/s12032-023-02228-x.
67.
LejmanMChałupnikAChilimoniukZDoboszM.Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in children. Int J Mol Sci. 2022;23(5):2755. doi:10.3390/ijms23052755.
68.
FangFYRosenblumJSHoWSHeissJD.New developments in the pathogenesis, therapeutic targeting, and treatment of pediatric medulloblastoma. Cancers. 2022;14(9):2285. doi:10.3390/cancers14092285.
69.
RultenSLGroseRPGatzSAJonesJLCameronAJ.The future of precision oncology. Int J Mol Sci. 2023;24(16):12613. doi:10.3390/ijms241612613.
70.
FalaschiZGiaconiCFanniSC, et al. Multimodality imaging of pediatrics tumors. In: NeriEErbaPA, eds. Multimodality Imaging and Intervention in Oncology. Cham: Springer; 2023:513-549. doi:10.1007/978-3-031-28524-0_21.
71.
PokornaPPalovaHAdamcovaS, et al. Real-world performance of integrative clinical genomics in pediatric precision oncology. Lab Invest. 2024;104(12):102161. doi:10.1016/j.labinv.2024.102161.
72.
SimonJReitaDGuerinE, et al. Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology. BMC Cancer. 2024;24(1):1296. doi:10.1186/s12885-024-13034-7.
73.
LarrosaCMoraJCheungN-K.Global impact of monoclonal antibodies (mAbs) in children: a focus on anti-GD2. Cancers. 2023;15(14):3729. doi:10.3390/cancers15143729.
74.
TerryRLMeyranDFleurenED, et al. Chimeric antigen receptor T cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma. Cancers. 2021;13(18):4704. doi:10.3390/cancers13184704.
75.
LeeWGKimES.Precision oncology in pediatric cancer surgery. Surg Oncol Clin N Am. 2024;33(2):409-446. doi:10.1016/j.soc.2023.12.008.
76.
FahmySADawoudAZeinelabdeenYA, et al. Molecular engines, therapeutic targets, and challenges in pediatric brain tumors: a special emphasis on hydrogen sulfide and RNA-based nano-delivery. Cancers. 2022;14(21):5244. doi:10.3390/cancers14215244.
77.
YaoQGorevicPShenBGibsonG.Genetically transitional disease: a new concept in genomic medicine. Trends Genet. 2023;39(2):98-108. doi:10.1016/j.tig.2022.11.002.
PiñeroJRodriguez FragaPSValls-MargaritJ, et al. Genomic and proteomic biomarker landscape in clinical trials. Comput Struct Biotechnol J. 2023;21:2110-2118. doi:10.1016/j.csbj.2023.03.014.
80.
MittalAKShekhawatDSJoshiVSinghPSinghK.Next-generation sequencing in newborn screening: a review on clinical and economic prospects. Open Biotechnol J. 2023;17(1):20226. doi:10.2174/18740707-v16-e221213-2022-6.
MustafaAS.Whole genome sequencing: applications in clinical bacteriology. Med Princ Pract. 2024;33(3):185-197. doi:10.1159/000538002.
83.
D’GamaAMAgrawalPB.Genomic medicine in neonatal care: progress and challenges. Eur J Hum Genet. 2023;31(12):1357-1363. doi:10.1038/s41431-023-01464-z.
84.
EdsjöAGisselssonDStaafJ, et al. Current and emerging sequencing-based tools for precision cancer medicine. Mol Aspects Med. 2024;96:101250. doi:10.1016/j.mam.2024.101250.
85.
FasaludeenAMcTagueAJoseM, et al. Genetic variant interpretation for the neurologist-A pragmatic approach in the next-generation sequencing era in childhood epilepsy. Epilepsy Res. 2024:107341. doi:10.1016/j.eplepsyres.2024.107341.
86.
AlimohamedMZSiimaAAManjiM.Advancing genetic testing for neurological disorders in Tanzania: importance, challenges, and strategies for implementation. Front Neurosci. 2024;18:1371372. doi:10.3389/fnins.2024.1371372.
87.
HosseiniSYMallickRMäkinenPYlä-HerttualaS.Navigating the prime editing strategy to treat cardiovascular genetic disorders in transforming heart health. Expert Rev Cardiovasc Ther. 2024;22(1-3):75-89. doi:10.1080/14779072.2024.2328642.
88.
AhmadAImranMAhsanH.Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel Biomarkers of diseases. Pharmaceutics. 2023;15(6):1630. doi:10.3390/pharmaceutics15061630.
89.
WatanabeHNaganoNTsujiYNotoNAyusawaMMoriokaI.Challenges of pediatric pharmacotherapy: a narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Eur J Clin Pharmacol. 2024;80(2):203-221. doi:10.1007/s00228-023-03598-x.
90.
TaoRHanXBaiX, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024;15:1354825. doi:10.3389/fimmu.2024.1354825.
91.
ElliottAM.Genetic counseling and genome sequencing in pediatric rare disease. Cold Spring Harb Perspect Med. 2020;10(3):a036632. doi:10.1101/cshperspect.a036632.
92.
FrenchCEAndrewsNCBeggsAH, et al. Hospital-wide access to genomic data advanced pediatric rare disease research and clinical outcomes. Npj Genom Med. 2024;9(1):60. doi:10.1038/s41525-024-00441-9.
93.
SullivanJASchochKSpillmannRCShashiV.Exome/genome sequencing in undiagnosed syndromes. Annu Rev Med. 2023;74(1):489-502. doi:10.1146/annurev-med-042921-110721.
94.
SinglaA.Precision medicine: tailoring treatment to individual genetic profiles. Shodh Sagar Journal for Medical Research Advancement. 2024;1(1):27-37. doi:10.36676/ssjmra.v1.i1.04.
95.
MarquesLCostaBPereiraM, et al. Advancing precision medicine: a review of innovative In Silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024;16(3):332. doi:10.3390/pharmaceutics16030332.
96.
van GroenBDAllegaertKTibboelDde WildtSN.Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport. Br J Clin Pharmacol. 2022;88(10):4285-4296. doi:10.1111/bcp.14534.
97.
YalçinNFlintRBvan SchaikRHNSimonsSHPAllegaertK.The impact of pharmacogenetics on pharmacokinetics and pharmacodynamics in neonates and infants: a systematic review. Pharmgenomics Pers Med. 2022;15:675-696. doi:10.2147/pgpm.s350205.
98.
BonilhaAE.Sequencing the baby’s genome: ethical and policy considerations for genetic counselors in newborn screening programs. McGill University (Canada); August 2023. Accessed March 29, 2025. https://escholarship.mcgill.ca/concern/theses/sf268b889.
99.
ParkerLS. Ethical considerations in precision medicine. In: BydonM, eds. The New Era of Precision Medicine. Amsterdam: Elsevier; 2024:143-172. doi:10.1016/B978-0-443-13963-5.00002-9.
100.
SarwarE.Global Perspectives on Precision Medicine: Ethical, Social and Public Health Implications. Cham: Springer Nature; 2023.
101.
KariyawasamDSScarfeJMeagherC, et al. Integrating ethics and equity with economics and effectiveness for newborn screening in the genomic age: a qualitative study protocol of stakeholder perspectives. PLoS ONE. 2024;19(3):e0299336. doi:10.1371/journal.pone.0299336.
102.
SubasriMCressmanCArjeD, et al. Translating precision health for pediatrics: a scoping review. Children. 2023;10(5):897. doi:10.3390/children10050897.
103.
PrabhakarPK.Biomedical Research Developments for Improved Healthcare. Hershey, PA: IGI Global; 2024. doi:10.4018/979-8-3693-1922-2.
104.
PapadopoulouPLytrasM.Advancing precision medicine in medical education: integrated, precise and data-driven smart solutions. Appl Res. 2023;2(6):e202200131. doi:10.1002/appl.202200131.
105.
YanHBytautasJIsenbergSR, et al. Grief and bereavement of family and friends around medical assistance in dying: scoping review. BMJ Support Palliat Care. 2023;13(4):414-428. doi:10.1136/spcare-2022-003715.
106.
FordeJ.The Irish Early Childhood Care and Education (ECCE) scheme is free and universal, but at whose expense?, 2022. Accessed May 25, 2025. https://sword.mtu.ie/allthe/541/.
